Applying ICER Assessments in Medicaid Could Limit Patients’ Access to Medicines

Report

Milliman Study on Limitations in Using ICER’s “Potential Budget Impact” Work to Guide Private Payer Budget Decisions

Report

Milliman Study on the Utility of ICER Reports for Private Payer Drug Coverage Decision-Making

Report

How ICER’s Flawed Budget Impact Threshold Can Harm Patient Access

Report

Using ICER’s Value Assessments Would Limit Access to Life-Saving Medicines in Medicare Part B

Report

Delivering Results for Patients: The Value of Value-Based Contracts

Report

Policy Solutions

Biopharmaceutical Company Communications with Health Care Stakeholders

Report

Policy Solutions: Promoting Value-Driven Health Care

PhRMA Comment on the Health Care Innovation Caucus Request for Information

Speeches & Communication

PhRMA Comments on CMS Proposed Rule on Changes to Medicaid

Speeches & Communication

PhRMA Comment on OIG Regulatory Sprint Proposed Rule

Speeches & Communication

PhRMA Comment: Call for Public Input on ICER Value Framework

Fact Sheet

PhRMA Comment Medical Product Communications That Are Consistent With the FDA Required Labeling Questions and Answers

Fact Sheet

Results-Based Contracting: The Need to Reconsider the Anti-Kickback Statute

Fact Sheet

How ICER’s Assessment of New Migraine Treatments Ignores Patient Needs

Fact Sheet

Biopharmaceutical Companies’ Personalized Medicine Research Yields Innovative Treatments for Patients

Fact Sheet

A Delicate Balance - Pharmaceutical Innovation and Access

Codes & Guidelines

Patient-Perspective Value Framework

Codes & Guidelines

PhRMA Positions on Quality and Performance Measurement

Codes & Guidelines

Principles for Value Assessment Frameworks

Codes & Guidelines

Responsible Sharing of Information About Medicines

Codes & Guidelines

PhRMA Policy Solutions_Delivering Innovative Treatments to Patients

Codes & Guidelines